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CARMINOMYCIN ANALOGUE
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a new anthracycline glyco­
side antineoplastic agent and, more particularly, to a 
new oxygen analogue of the anthracycline antibiotic 
carminomycin.
2. Prior Art
As described in M. G. Brazhnikova et al., J. Antibiot., 
27:254-259 (1974), G. F. Gause et al, Cancer Chemother. 
Rep. 58:255-256 (1974), M. C. Wani et al, J. Am. Chem. 
Soc. 97:5955-5956 (1975) and West German Pat. No. 
2,362,707, the anthracycline glycoside carminomycin is 
known to be a clinically useful antineoplastic agent. 
However, it produces certain undesirable side effects, 
common to many antineoplastics agents, which limit its 
use in chemotherapy. In particular, it produces a cumu­
lative, dose-related cardiotoxicity which limits the total 
dosage that can be administered to a patient and the 
duration of treatment.
Preparation of a glycoside of daunorubicin is de­
scribed in E, F. Fuchs et al, Carbohydr. Res., 57: C36 
(1977). Preparation of glycosides of e-rhodomycinone is 
described in H. S. El Khadem et al, J. Med. Chem., 
20:957-960 (1977). Preparation of 2-deoxy-L-
fucopyranosyl-e-pyrromycinone and 2-deoxy-D-ery- 
thro-pentopyransoly-e-pyrromycinone, - cdaunomyci- 
none, and - carminomycinone and their dio-O-acetyl 
derivatives is described in H. S. El Khadem, Carbohydr. 
Res., 65: Cl (1978).
SUMMARY OF THE INVENTION
The present invention provides a new oxygen ana­
logue of carminomycin which can be represented by the 
following formula:
This carminomycin analogue can be prepared by cou­
pling an appropriate glycosyl halide, namely, 3,4-di-O- 
acetyl-2,6-dideoxy-a-L-lyxo-hexopyranosyl bromide, 
or the corresponding chloride, to carminomycinone. 
The resulting acetylated blocked glycoside intermedi­
ate is deacetylated to produce the above oxygen ana­
logue of carminomycin which is effective for inhibiting 
the growth of tumors such as leukemia L1210.
The invention also provides a method for inhibiting 
the growth of certain mammalian tumors such as L1210 
leukemia by administering therapuetically effective 
amounts of the above compound to experimental ani­
mals afflicted with such tumors.
2
DETAILED DESCRIPTION
The overall reaction scheme of a preferred process 
for preparing the novel carminomycin analogue of the 
invention can be represented as follows:
(IV)
wherein X is Br or Cl.
The starting compound carminomycinone (I) can be 
prepared in a conventional manner such as by hydrolyz­
ing carminomycine. This can be accomplished by re­
fluxing a 0.1 N hydrochloric solution of carminomycin 
for 2-3 hours and filtering the precipitate carminomyci­
none crystals from the solution.
The glycosyl halide 3,4-di-0-acetyl-2,6-dideoxy-a-L- 
lyxo-hexopyranosyl bromide or chloride (II) coupled 
with carminomycinone can be prepared in the manner 
as described in H. S. El Khadem et al, Carbohydr. Res., 
58:230-234 (1977). That is, L-fucose tetraacetate is 
treated with hydrogen bromide in acetic acid to obtain 
the corresponding glycosyl bromide which is treated 
with an activated zinc dust suspension at a reduced 
temperature, the cold mixture filtered and the filtrate 
extracted with chloroform or the like. The resulting 
di-O-acetyl-L-fucal is treated with a dry stream of hy­
drogen bromide or hydrogen chloride to produce the 
desired glycosyl halide.
The coupling reaction is carried out by refluxing one 
molar equivalents of carminomycinone and the glycosyl 
halide under Koenig-Knorr conditions using a mercuric
5
10
15
20
25
30
35
40
45
50
55
60
65
4,302,449
bromide-mercuric cynanide catalyst. The reaction 
product is filtered to remove solids and the mercuric 
salts. The filtrate is evaporated to dryness to remove the 
solvent. The solid residue is dissolved in a suitable sol­
vent, such as chloroform, and the resulting solution is 
washed to remove remaining mercuric salts. After the 
solution is evaporated to dryness, the resulting solid 
residue is dissolved in a suitable solvent, such a diethyl 
ether, and sugar components which do not react with 
carminomycinone are removed in a suitable manner, 
such as with a column chromatograph, to yield the 
blocked acetylated glycoside intermediate (III).
The glycoside intermediate (III) is deacetylated in a 
suitable manner to produce the carminomycin analogue 
of the invention. This can be accomplished by dis­
solving the acetylated glycoside in a suitable solvent, 
such as methanol, and adding the solution to a sodium 
methoxide-methanoi solution containing an excess of 
sodium methoxide. The desired carminomycinone ana­
logue 2-deoxy-L-fucopyranosyl carminomycinone (IV) 
is extracted by chloroform or the like.
The compound of the invention can be used as an 
active ingredient in pharmaceutical compositions in­
cluding a pharmaceutically acceptable carrier. Such 
compositions could also include one or more active 
antibacterial and/or antineoplastic agents and may be in 
any form suitable for the desired mode of administra­
tion. For instance, the pharmaceutical composition can 
be in a solid form for oral administration, such as tablets, 
powders, granules or capsules, liquid form for oral ad­
ministration such as syrups, solutions or suspensions and 
liquid preparations for parenteral administration, such 
as solutions, emulsions, or suspensions.
The pharmaceutical composition is administered in 
dosages which provide a concentration of the car­
minomycinone glycoside greater than the minimum 
inhibitory concentration for the leukemia tumor. The 
actual dosage will vary depending on such things as the 
formulation of the composition, mode of administration, 
age, weight, diet and reaction sensitivities of the af­
flicted host, and severity of the tumor. It is well within 
the skill of the art, after reviewing the guidelines dis­
closed herein, to determine the optimum dosage for a 
given situation by using conventional dosage tests.
Without further elaboration, it is believed one skilled 
in the art can, by using the preceeaing description, 
utilize the present invention in its fullest extent. The 
following examples are presented for the purpose of 
illustration and should not be construed as 'limitations to 
the invention.
EXAMPLE 1
Preparation of 2-deoxy-L-fucopyranosyl 
carminomycinone
300 mg of carminomycin in 30 ml of 0.! N hydrochlo­
ric acid was refluxed with stirring for 3 hours. This 
solution was cooled and filtered. The wet red crystals 
were dried in a vacuum desiccator over sodium hydrox­
ide overnight to yield about 200 mg of carminomyci­
none (I).
A mixture comprising 200 mg carminomycinone, 1.0 
g finely divided molecular sieves 3A, 200 mg mercuric 
bromide, 20 mg mercuric cynnanide, 200 mg 3,4-di-O- 
acetyl-2,6-dideoxy-a-lyxo hexopyranosyi bromide (II) 
and 20 ml tetrahydrofuran was refluxed with stirring for
3
1 hour. An additional 200 mg of the glycosyl bromide 
was added to the mixture and the mixture refluxed for 
another hour. The solution was filtered to remove the 
molecular sieves and the mercuric compounds and the 
sieves were washed with chloroform. The combined 
filtrates were evaporated to dryness, the solid residue 
dissolved in chloroform and the resulting solution was 
washed several times with a 20% potassium iodide solu­
tion to remove remaining mercuric compounds. The 
solution was then dried over anhydrous sodium sulfate 
and evaporated to dryness. The solid residue was dis­
solved in absolute diethyl ether containing a small 
amount of chloroform and the solution was applied to a 
silica gel column chromatograph (washed with absolute 
diethyl ether) to remove sugar components which had 
not reacted with carminomycinone. The blocked acety- 
leted glycoside intermediate (III) was eluded with chlo­
roform containing 3% methanol.
The glycoside-containing fractions from the chro­
matograph were evaporated to dryness. The solid resi­
due was dissolved in 20 ml of methanol and the resulting 
solution was added to a freshly prepared, room temper­
ature sodium methoxide/methanol solution containing 
an excess of sodium methoxide to deacetylate the glyco­
side. After 20 minutes, the solution was poured into a 
separatory funnel containing a sodium hydrogen sulfate 
solution and the desired oxygen analogue of carmino­
mycin (IV) was extracted with chloroform. The extract 
was dried over anhydrous sodium sulfate and evapo­
rated to dryness. The solid residue was dissolved in 40 
ml of hoi 95% methanol and the resulting solution was 
filtered and reduced in volume to about 10 ml. After 
cooling, the crystals were filtered and washed with 
ethanol and ether to yield about 100 mg of 2-deoxy-L- 
fucopyranosyl carminomycinone (IV) having a melting 
point of 228°~232° C. Elemental analysis of the material 
gave the following results:
Calculated weight percent for C26H26O 11, 0.5 H2O: 
0 =  59.65, 11=5.20. Found: C=59, H=4.91.
The structure for the glycoside (IV) was confirmed 
by its n.m.r. spectrum.
EXAMPLE 2 
Bilogica! Activity
The carminomycinone glycoside prepared by the 
procedure described in Example 1 was tested against 
transplanted mouse leukemia L 1210 according to the 
procedures described in Cancer Chemother, Rep., 
3:1-87, Pari 3 (1972). Two experiments were con­
ducted. The mice were given a single treatment in the 
first experiment and the mice were given both a single 
treatment and a daily injection for 9 days (QD 1—>9) in 
the second experiment.
The test results are summarized in Table I. From 
these data, it can be seen that the survival time of tumor 
bearing animals was increased 86% over the control in 
the first experiment and at least one dose for each type 
of treatment in the second experiment increased the 
survival time by 71%.
From the foregoing description, one skilled in the art 
can easily ascertain the essential characteristics of the 
invention, and without departing from the spirit and 
scope thereof, can make various changes and modifica­
tions to adapt it to various usages.
We claim:
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TABLE I
EFFECT OF CARMINOMYCINONE 
GLYCOSIDE (CG) ON L 1210 LEUKEMIA
Experiment
No. Material
Treatment
Regimen
Dose,
mg/kg/day
MST,
Days
Effect 
MST, 
% T /C
Average 
Weight 
Change, g
Survivors, 
Day 5
1 CG Once, Day 1 12.8 13.0 186 -0 .4 6/6
i 6.4 9.5 136 -1 .1 6/6
l 3.2 8.0 114 -0 .9 6/6
1 1.6 7.5 107 -0 .8 6/6
1 0.8 8.0 114 +  1.2 6/6
i 0.4 7.0 107 -0 .8 6/6
Control (saline) i — 7.0 — +2.2 10/10
2 CG Once, Day 1 51.2 12.0 171 -1 .9 5/6
i 25.6 11.5 164 -1 .2 6/6
i 12.8 9.5 136 +0.3 6/6
i 6.4 11.0 157 +0.7 6/6
i 3.2 8.0 114 +0.2 6/6
i 1.6 9.0 129 -0 .6 6/6
QD 1 — 9 12.8 8.0 114 -1 .6 5/6
i 6.4 12.0 171 -1 .7 6/6
1 3.2 11.0 157 -0 .3 5/6
1 1.6 8.5 121 -0 .6 6/6
1 0.8 8.0 114 +2.3 6/6
1 0.4 8.0 114 +0.6 6/6
Control (saline) — 7.0 — +  1.9 10/10
Tumor Inoculum: 1G6 ascites cells implanted i.p. into BDFj female mice.
Evaluation: MST =  median survival time in days; % T /C  =  MST treated/MST control X 100. 
Criteria: % T /C  =  125 considered significant antitumor effect.
1. A compound having the formula:
2. A method of inhibiting the growth of L  1210 leuke­
mia tumors comprising administering to an experimen­
tal animal host afflicted with said tumor a composition 
including an amount of a compound according to claim 
1 sufficient to inhibit the growth of said tumor and a 
pharmaceutically acceptable carrier.
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